A PHASE 1B STUDY OF SUBCUTANEOUS DARATUMUMAB REGIMENS IN COMBINATION WITH BISPECIFIC T CELL REDIRECTION ANTIBODIES FOR THE TREATMENT OF SUBJECTS WITH MULTIPLE MYELOMA
2019-000330-19MIELOMA MULTIPLEFundación Jiménez DíazInvestigador: ASKARI ASKARI ELHAM